National Cancer Institute  U.S. National Institutes of Health

Cancer Trends Progress Report – 2007 Update

Progress Report  Home

Progress Report Tools
 Print this page
 Generate custom report

Also in this Section
Breast Cancer Treatment
Colorectal Cancer Treatment

Also in the Report
Report Highlights
Summary Tables
Early Detection
Life After Cancer
End of Life

Colorectal Cancer Treatment

The proportion of patients receiving appropriate adjuvant therapy has increased steadily since 1987. Potential disparities remain for some groups of patients.

Note: Updated adjuvant therapy information for stage II and III colorectal cancer will be available in early 2009.

On this page:

Benefits of Treatment

On the basis of accumulated evidence from clinical trials, a 1990 NIH Consensus Development Conference recommended that patients with stage III colon cancer be given adjuvant chemotherapy. The 1990 NIH Consensus Conference also recommended combined adjuvant chemotherapy and high-dose external-beam radiotherapy for stage II and III rectal cancer. Radiation does not appear to affect disease-specific or overall survival for rectal cancer, although it does decrease local recurrence.

Back to Top


Percent of individuals, ages 20 and over, diagnosed with stage III colon cancer who received 5-FU plus either levamisole or leucovorin or diagnosed with stage II or stage III rectal cancer who received 5-FU with or without radiotherapy.

Back to Top

Period – 1987–2000

Back to Top

Trends – Rising, rapidly between 1987 and 1990, rising moderately between 1990 and 2000.

Back to Top

Most Recent Estimates

In 2000, 57 percent of stage III colon, and stage II and III rectal patients ages 20 and older received adjuvant chemotherapy.

Back to Top

Healthy People 2010 Targets

There are no Healthy People 2010 targets for cancer treatment including for colorectal cancer treatment.

Back to Top

Groups at High Risk for Not Receiving Appropriate Treatment

Studies have found that older colorectal patients are less likely to receive adjuvant chemotherapy treatment, even after adjustment for the higher rate of pre-existing co-morbid conditions among older patients. Even elderly patients with no or very few co-morbid conditions, such as diabetes, kidney, or heart disease, were less likely to receive treatment. Earlier studies indicated that Black patients were less likely to receive treatment than White patients; however, this disparity was not found in the 2000 NCI Patterns of Care/Quality of Care study.

Back to Top

Key Issues

Chemotherapy for colorectal cancer is a rapidly evolving field. Emerging treatments include chemotherapy regimens that incorporate irinotecan and/or oxaliplatin agents that interfere with DNA synthesis during cancer cell division and, more recently, anti-angiogenesis agents. These newer drugs result in better outcomes for many colorectal cancer patients but they also are much more expensive than earlier treatments.

Back to Top

Additional Information on Colorectal Cancer Treatment

Back to Top

National Cancer InstituteDepartment of Health and Human ServicesNational Institutes of